


# Neurofibrosarcoma Treatment Market to Surge USD 3317.10 Mn by 2032

Neurofibrosarcoma Market size was valued at USD 1567.86 Mn in 2024, to grow at a CAGR of 9.82% from 2025 to 2032, reaching nearly USD 3317.10 Mn by 2032.

WILMINGTON, DE, UNITED STATES, September 11, 2025 / EINPresswire.com/ -- The [Neurofibrosarcoma Treatment Market](#) to rise from USD 1567.86 million in 2024 is to expect USD 3317.10 million by 2032, expanding at a CAGR of 9.82% during the forecast period. North America and Europe leading in clinical trials supported by regulatory incentives and rare cancer funding frameworks.



The recent report published by Stellar Market Research on Neurofibrosarcoma Treatment Market covers Emerging Therapies, Strategic Insights, Market Dynamics, Regional Landscape, Segmentation, Key Trends, and Major Players.

“

The neurofibrosarcoma treatment market is driven by advances in targeted therapies, growing clinical trials, and rising demand for precision medicine to improve patient outcomes and survival rates.”

Navneet Kaur

## Neurofibrosarcoma Treatment Market Overview

The Neurofibrosarcoma Treatment encompasses the diagnosis, management, and therapeutic solutions for malignant peripheral nerve sheath tumors (MPNSTs). It includes surgical, radiotherapy, chemotherapeutic, and emerging targeted approaches aimed at improving patient outcomes worldwide.

The Stellar Market Research report highlights the global incidence of Neurofibrosarcoma cases

by country and provides detailed insights into available treatment processes, including surgery, radiation, chemotherapy, and emerging targeted therapies. It also delivers a comprehensive country- and region-level analysis, covering treatment trends, strategic market opportunities, and the competitive landscape, with profiles of key regional players, their revenue, growth rate, clinical trials, and patents, making it an essential resource for investors, healthcare strategists, and industry stakeholders.

Global Neurofibrosarcoma Treatment Market Segments Covered	
By Type	Malignant Peripheral Nerve Sheath Tumor (MPNST) Desmoid Tumors Plexiform Neurofibromas Solitary Neurofibromas Others
By Treatment	Surgery Radiation Therapy Chemotherapy Others
By Administration Type	Oral Administration Intravenous Administration Subcutaneous Administration Topical Administration
By Region	<b>North America</b> (United States, Canada and Mexico) <b>Europe</b> (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe) <b>Asia Pacific</b> (China, India, Japan, South Korea, Australia, ASEAN (Indonesia, Malaysia, Myanmar, Philippines, Singapore, Thailand, Viet Nam etc.) and Rest of APAC) <b>Middle East and Africa</b> (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) <b>South America</b> (Brazil, Argentina, Colombia and Rest of South America)

Neurofibrosarcoma Treatment Market

□ Access the full Research Description at: [https://www.stellarmr.com/report/req\\_sample/Neurofibrosarcoma-Treatment-Market/2800](https://www.stellarmr.com/report/req_sample/Neurofibrosarcoma-Treatment-Market/2800)

Key Insights & Recent Developments

The Neurofibrosarcoma (MPNST) Treatment Market addresses a rare malignancy affecting 1 in 3,000 globally, with 8–13% lifetime incidence in NF1 patients. Limited chemotherapy efficacy, reliance on surgical resection, and the pipeline of targeted therapies highlight the high unmet clinical need and market growth potential.

About 15% of people with NF1 develop brain tumors, primarily astrocytomas and optic pathway gliomas, in childhood.

The report provides an in-depth analysis of key players, treatment diagnostics, and therapeutic options, covering surgery, radiation therapy, chemotherapy, and emerging targeted and immunotherapy approaches.

Recent developments focus on orphan drug designations, clinical trial expansion, and regulatory incentives, which are accelerating research in advanced therapies. These advancements are reshaping the competitive landscape and opening opportunities for biotech innovators.

Neurofibrosarcoma Treatment Market Dynamics

Rising NF1 prevalence and MPNST risk, along with the adoption of targeted therapies, orphan drugs, and precision medicine, are driving market growth, supported by expanding clinical trials and strong regulatory backing.

Advances in novel therapies, increasing integration of precision medicine and genetic testing for

NF1 patients, early diagnostics, and growing public-private collaborations present strong opportunities, while rare cancer awareness and improved patient registries enhance market reach across developed and emerging regions.

Key restraints include limited chemotherapy success, high treatment costs, and the disease's rarity, which limit investment. Surgical complexity, poor prognosis in advanced cases, and lack of standardized protocols remain ongoing challenges.

## Neurofibrosarcoma Treatment Market Regional Analysis

The report provides a detailed breakdown of the market across major regions:

**North America:** The largest market, driven by strong clinical trial activity, advanced diagnostic infrastructure, and orphan drug incentives in the U.S.

**Europe:** Significant market supported by rare disease frameworks, cross-border treatment centers, and government-backed research in countries like Germany, UK, and France.

**Asia-Pacific:** Emerging market with growing awareness, expanding healthcare infrastructure, and rising focus on rare cancer management in China, Japan, and India.

## Neurofibrosarcoma Treatment Segmentation

The segments of the market based on By Type and By Treatment, By Administration Type

**By Type:** Malignant Peripheral Nerve Sheath Tumor (MPNST) dominates due to its aggressive nature, followed by Desmoid Tumors, Plexiform Neurofibromas, Solitary Neurofibromas, and Others.

**By Treatment:** Surgery is the primary treatment, with Radiation Therapy and Chemotherapy used in advanced cases, while targeted therapies are emerging.

## Neurofibrosarcoma Treatment Market Trends

The report highlights growing research in targeted therapies and immunotherapies as a key trend, addressing limitations of traditional chemotherapy.

Increasing focus on early diagnostics and genetic testing is shaping treatment pathways and improving patient outcomes.

Rising collaborations between pharma companies and research institutes are accelerating drug development and clinical trials for rare tumors

□ Access the full Research Description at:

[https://www.stellarmr.com/report/reg\\_sample/Neurofibrosarcoma-Treatment-Market/2800](https://www.stellarmr.com/report/reg_sample/Neurofibrosarcoma-Treatment-Market/2800)

## Competitive Landscape

The SMR Competition Matrix for the Neurofibrosarcoma Treatment Market provides a detailed analysis emphasizing top pharmaceutical and biotech players' innovative therapies and strategic positioning. Company profiles cover headquarters, business portfolios, revenue, market share, clinical trial activity, patents, and end-user focus. Key Players Benchmarking evaluates financial performance, technological advancements, and market presence, highlighting competitive strengths and growth opportunities. The analysis also categorizes companies into market leaders, followers, and emerging innovators. Insights into R&D initiatives, clinical trial pipelines, and regulatory approvals demonstrate the market's dynamic evolution. Historical and current data enable stakeholders to understand treatment trends, therapy adoption, and strategic developments shaping the global market

The report profiles key players in the market, including

### Neurofibrosarcoma Treatment Market Key Players

#### North America

Pfizer Inc. (USA)  
Bristol-Myers Squibb (USA)  
AbbVie Inc. (USA)  
Amgen Inc. (USA)  
SpringWorks Therapeutics (USA)  
Eli Lilly and Company (USA)  
Merck & Co., Inc. (USA)  
Johnson & Johnson (USA)

#### Europe

Hoffmann-La Roche Ltd (Switzerland)  
Novartis AG (Switzerland)  
GlaxoSmithKline plc (GSK) (United Kingdom)  
Sanofi S.A. (France)  
Bayer AG (Germany)  
AstraZeneca plc (United Kingdom)  
Ipsen S.A. (France)  
Servier Laboratories (France)

#### Asia Pacific

Takeda Pharmaceutical Company Limited (Japan)

Reddy's Laboratories (India)  
Sun Pharmaceutical Industries Ltd. (India)  
Chugai Pharmaceutical Co., Ltd. (Japan)  
Eisai Co., Ltd. (Japan)  
Zydus Lifesciences Ltd. (India)  
Middle East and Africa

Hikma Pharmaceuticals (Jordan)  
Aspen Pharmacare Holdings Ltd. (South Africa)  
South America

EMS Pharma (Brazil)  
Eurofarma Laboratórios (Brazil)  
Blanver Farmoquímica Ltda. (Brazil)  
Related Reports:

Burial Insurance Market: <https://www.stellarmr.com/report/burial-insurance-market/2804>

Pseudotumor Cerebri Market: <https://www.stellarmr.com/report/Pseudotumor-Cerebri-Market/2799>

Resuscitation Devices Market: <https://www.stellarmr.com/report/Resuscitation-Devices-Market/2798>

Vacuum Therapy Devices Market: <https://www.stellarmr.com/report/Vacuum-Therapy-Devices-Market/2786>

About Stellar Market Research:

Stellar Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.

Contact Stellar Market Research:

S.no.8, h.no. 4-8 Pl.7/4, Kothrud,  
Pinnac Memories Fl. No. 3, Kothrud, Pune,  
Pune, Maharashtra, 411029

sales@stellarmr.com

Lumawant Godage  
Stellar Market Research  
+ +91 9607365656

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/848144186>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.